GlassScriptPhysician profile
Richard D Purcell
NPI 1881689933
$5,439.22
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,158 · 2020: $1,304 · 2021: $1,140 · 2022: $1,135 · 2023: $342 · 2024: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $438 · Travel and Lodging: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.65 |
| Travel and Lodging | $264.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,152.62 | 2019-2022 | |
| Zimmer Biomet Holdings, INC. | $731.97 | 2019-2024 | Avitus Bone Harvester |
| E.R. Squibb & Sons, L.L.C. | $408.49 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $384.83 | 2020-2022 | |
| Glaxosmithkline, LLC. | $376.21 | 2019-2022 | |
| Janssen Biotech, INC. | $339.97 | 2019-2022 | |
| Abbvie INC. | $314.17 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $272.16 | 2019-2022 | |
| Octapharma USA, INC. | $193.11 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $190.42 | 2019 | |
| Pfizer INC. | $165.15 | 2019-2022 | |
| Genentech USA, INC. | $163.06 | 2019-2022 | |
| Radius Health, INC. | $146.77 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $146.71 | 2019-2022 | |
| Horizon Therapeutics Plc | $96.99 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $78.02 | 2019 | |
| Merck Sharp & Dohme LLC | $53.70 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.39 | 2021 | |
| Csl Behring | $26.89 | 2020 | |
| Kaleo, INC. | $24.89 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $24.36 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.73 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.83 | 2021 | |
| Allergan, INC. | $16.27 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.96 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.39 | 2021 | |
| Ucb, INC. | $12.61 | 2022 | |
| Genzyme Corporation | $12.35 | 2020 | |
| Lilly USA, LLC | $12.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Purcell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.